IPF

Quote

<



Perhaps being acquired by a company with deep pockets has precipitated more resources being allocated to a launch of a new molecule in a market that has previously had no therapies and now has two? Expansion, in other words.
 








I can answer this for you. They have a drug that's about to be approved for a rare fatal lung disease, IPF. They just hired a very expensive pulmonology sales force of 80 reps. These reps make between 130-150K base salary and have been paid 85K in sign on, retention, and accelerated RSUs. They are also guaranteed a 1 year severance if laid off by Roche. The reps haven't been trained yet. Intermune also has a hep C drug in development. No oncology pipeline.
 




FYI... Drug was approved last week and all the reps have completed training. As far as the expansion goes... They will interview internal Genentech people first. They will look outside for the positions aren't filled internally.
 




Any insight on who is leading this team? As a former Pegasys CS, I made the decision to leave earlier this year but really miss the company and culture and am considering applying for one of the open positions. Thanks for any input
 








Why not...we are specialist, we have been working in biotech for 4 years, pegasys is a highly special drug. Don't we wake up int he morning, brush out teeth, wash our faces and put on pants just like any other GNE rep???
 








Similar threads

Name of RD for IPF
Replies
4
Views
4K
Genentech
Anonymous
Top Bottom
Back
Quote